<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39401679</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>Immuno-persistence after the 4<sup>th</sup> and 5<sup>th</sup> dose of inactivated polio vaccines in school-aged children.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(24)00489-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2024.10.007</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to assess the long-term persistence of neutralising antibodies (nAb) titres and seroprotection proportions after the 4<sup>th</sup> and 5<sup>th</sup> doses of inactivated polio vaccine (IPV).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Serum samples from 299 children in Hong Kong were collected and used to estimate the persistence of nAb titres and seroprotection proportions by neutralisation test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean nAb titres against polioviruses type 1, 2 and 3 (PV1, PV2 and PV3) one month after receiving the 4<sup>th</sup> dose of IPV at 19 months of age were 2,068 (95% credible interval: 1,517 - 2,864), 4,705 (3,439 - 6,436) and 2,758 (1,894 - 4,086), but declined substantially in 4 years to 268 (222 - 325), 751 (630 - 900), and 411 (323 - 521), respectively. Administration of the 5<sup>th</sup> dose of IPV restored nAb titres among children aged 6-7 years, and the decline in nAb titres was slightly slower with the estimated mean titres of 355 (272 - 462), 538 (427 - 681), and 548 (378 - 786) against PV1, PV2, and PV3 at 4 years post the 5<sup>th</sup> dose. We estimated that the proportion of children who were seroprotected against PV1, PV2 and PV3 would drop below 90% at: (i) 8.2, 10.8, 8.7 years after the 4<sup>th</sup> dose; and (ii) 11.6, 11.2, 11.0 years after the 5<sup>th</sup> dose.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results revealed the immuno-persistence after the 4th and 5th dose of IPV and highlighted the importance of completing immunization series to ensure high vaccination coverage, particularly among children in the developing countries affected by the COVID-19 pandemic.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Kathy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health Limited (D(2)4H), Hong Kong Science Park, Hong Kong SAR, China; The University of Hong Kong - Shenzhen Hospital, Shenzhen, China. Electronic address: ksmleung@hku.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Chrissy W K</ForeName><Initials>CWK</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health Limited (D(2)4H), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Tiffany H K</ForeName><Initials>THK</Initials><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health Limited (D(2)4H), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-Zambrano</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Global Medical Affairs, Sanofi, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petit</LastName><ForeName>Céline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Global Immunology, Sanofi, Marcy-l'Etoile France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Tommy T Y</ForeName><Initials>TTY</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health Limited (D(2)4H), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Eric H Y</ForeName><Initials>EHY</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health Limited (D(2)4H), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Joseph T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health Limited (D(2)4H), Hong Kong Science Park, Hong Kong SAR, China; The University of Hong Kong - Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflict of interest KL, CWKP, THKL, TTYL, EHYL and JTW declare that there was no conflict of interest. JCVZ and CP are employees of Sanofi.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39401679</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2024.10.007</ArticleId><ArticleId IdType="pii">S1198-743X(24)00489-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle>